Literature DB >> 19796846

Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation.

Michael Schöll1, Ove Almkvist, Karin Axelman, Elka Stefanova, Anders Wall, Eric Westman, Bengt Långström, Lars Lannfelt, Caroline Graff, Agneta Nordberg.   

Abstract

Six young related pre-symptomatic carriers of a His163Tyr mutation in the presenilin 1 gene who will develop early onset familial Alzheimer's disease (eoFAD), and a control group of 23 non-carriers underwent (18)F-fluorodeoxyglucose positron emission tomography (FDG PET). The mutation carriers were followed-up after 2 years. Multivariate analysis showed clear separation of carriers from non-carriers on both occasions, with the right thalamus being the region contributing most to group differentiation. Statistical parametric mapping (SPM) revealed in the carriers non-significantly lower thalamic cerebral glucose metabolism (CMRglc) at baseline and significantly decreased CMRglc in the right thalamus at follow-up. One mutation carrier was followed-up with FDG PET 10 years after baseline and showed reductions in cognition and CMRglc in the posterior cingulate and the frontal cortex. This subject was diagnosed with AD 1 year later and assessed with an additional FDG as well as an (11)C-PIB PET scan 12 years after baseline. Global cortical CMRglc and cognition were distinctly decreased. PIB binding was comparable with sporadic AD patterns but showing slightly higher striatal levels.
Copyright © 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796846     DOI: 10.1016/j.neurobiolaging.2009.08.016

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  20 in total

1.  Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease.

Authors:  Meredith N Braskie; Luis D Medina; Yaneth Rodriguez-Agudelo; Daniel H Geschwind; Miguel Angel Macias-Islas; Paul M Thompson; Jeffrey L Cummings; Susan Y Bookheimer; John M Ringman
Journal:  Hum Brain Mapp       Date:  2012-07-17       Impact factor: 5.038

Review 2.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.

Authors:  Eric M Reiman; Jessica B S Langbaum; Pierre N Tariot
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

3.  Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly.

Authors:  Lidia Glodzik; Lisa Mosconi; Wai Tsui; Susan de Santi; Raymond Zinkowski; Elizabeth Pirraglia; Kenneth E Rich; Pauline McHugh; Yi Li; Schantel Williams; Fahad Ali; Henrik Zetterberg; Kaj Blennow; Pankaj Mehta; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2011-05-06       Impact factor: 4.673

Review 4.  Brain imaging in the study of Alzheimer's disease.

Authors:  Eric M Reiman; William J Jagust
Journal:  Neuroimage       Date:  2011-12-07       Impact factor: 6.556

Review 5.  Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention.

Authors:  Richard J Caselli; Eric M Reiman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 6.  The use of PET in Alzheimer disease.

Authors:  Agneta Nordberg; Juha O Rinne; Ahmadul Kadir; Bengt Långström
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

Review 7.  Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.

Authors:  Alexander Drzezga; Daniele Altomare; Cristina Festari; Javier Arbizu; Stefania Orini; Karl Herholz; Peter Nestor; Federica Agosta; Femke Bouwman; Flavio Nobili; Zuzana Walker; Giovanni Battista Frisoni; Marina Boccardi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-13       Impact factor: 9.236

Review 8.  Ushering in the study and treatment of preclinical Alzheimer disease.

Authors:  Jessica B Langbaum; Adam S Fleisher; Kewei Chen; Napatkamon Ayutyanont; Francisco Lopera; Yakeel T Quiroz; Richard J Caselli; Pierre N Tariot; Eric M Reiman
Journal:  Nat Rev Neurol       Date:  2013-06-11       Impact factor: 42.937

9.  Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Authors:  Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Napatkamon Ayutyanont; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Hua Mo; Liliana Lopez; Sonia Moreno; Natalia Acosta-Baena; Margarita Giraldo; Gloria Garcia; Rebecca A Reiman; Matthew J Huentelman; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  Lancet Neurol       Date:  2012-11-06       Impact factor: 44.182

Review 10.  Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals.

Authors:  Maciej J Lazarczyk; Patrick R Hof; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  BMC Med       Date:  2012-10-25       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.